Does a continuous-flow left ventricular assist device combined with pharmacological therapy improve reversal of severe heart failure in patients with end-stage heart failure secondary to nonischemic cardiomyopathy?
A combination of a continuous-flow LVAD and pharmacological therapy can achieve reversal of end-stage heart failure in patients with nonischemic cardiomyopathy.
Reversal of end-stage heart failure secondary to nonischemic cardiomyopathy can be achieved in a substantial proportion of patients with nonpulsatile flow through the use of a combination of mechanical and pharmacological therapy.
Birks et al. (Mon,) studied this question.